Home API Alogliptin Benzoate

Alogliptin Benzoate

Enquire Now

[anr_nocaptcha g-recaptcha-response]

What is Alogliptim Benzoate?

Alogliptin is a selective, orally bioavailable dipeptidyl peptidase-4 (DPP-4) inhibitor. It increases the amount of insulin produced by your body. Besides controlling Type-2 diabetes, Alogliptin Benzoate may also eliminate the cardiovascular disease by preventing the toll-like receptor 4 (TLR-4). These receptors can increase the chances of inflammation, further increasing the atherosclerotic disease process, the main cause of cardiovascular disease. 

Product Description

Molar Weight: 339.4

SMILES: CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.C1=CC=C(C=C1)C(=O)O

InChIKey: ZSBOMTDTBDDKMP-OAHLLOKOSA-N

ALogP: 0.39

Solubility: DMF: 0.1 mg/ml, DMSO: 0.1 mg/ml, Ethanol: slightly soluble, PBS (pH 7.2): 10 mg/ml

Storage: -20°C

Stability: ≥ 2 years

CAS Number: 850649-62-6

Chemical Formula: C18H21N5O2•C7H6O2

Therapeutic Category: Antidiabetic

Form: Tablet

Assay: NLT 99.0%

Suitable for: Adults

IUPAC Name: 2-({6-[(3R)-3­aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile monobenzoate

 

Alogliptin Benzoate

Approved Indications: 1

As per the clinical trials, there is one approved indication of Alogliptin Benzoate drug:

  • Diabetes Mellitus, Type-2

Experimental Indications: 7

As per clinical trials 1-4, the drug can be used in the following categories: 

  • Acute Coronary Syndrome (Phase 3)
  • Diabetes Mellitus ()
  • Diabetes Mellitus, Type 2 ()
  • Healthy Volunteers (Phase 1)
  • Non-alcoholic Fatty Liver Disease (Phase 4)
  • Pharmacokinetics (Phase 1)
  • Pharmacology, Clinical (Phase 3)

Clinical Trials:

A total of 60 trials took place in 4 phases. 13 organizations participated in these trials.

Side Effects

Major side effects observed after the consumption of Alogliptin are:

  • Upper respiratory tract infection
  • Common cold
  • Headache

Conclusion

Alogliptin Benzoate is an orally bioavailable dipeptidyl peptidase 4 (DPP-4) inhibitor used to treat type-2 diabetes. The drug has a molar mass of 339.4 g/mol and does not inhibit cytochrome P450 enzymes. The drug is actively used in making medications for type-2 diabetes patients. Besides that, it also has several other experimental indications, including Acute Coronary Syndrome, Non-alcoholic Fatty Liver Disease, etc. Some common side effects are headaches and the common cold.

Product CAS No

850649-62-6

Therapeutic Action

Alogliptin increasing the amount of insulin in our body, which is a type of hormone that control sugar leval in our blood in people with type 2 diabetes, also help prevent kidney damage.

Enquire Now
close slider


[anr_nocaptcha g-recaptcha-response]




  • INQUIRY FORM

    INQUIRY FORM